ABHD12 (Alpha/Beta Hydrolase Domain Containing 12) encodes a brain-enriched serine hydrolase enzyme that plays critical roles in lipid metabolism, endocannabinoid signaling, and neuroimmune function. ABHD12 is highly expressed in the central nervous system, particularly in neurons, microglia, and oligodendrocytes, where it hydrolyzes various lipid substrates including monoacylglycerols (MAGs), phospholipids, and fatty acid derivatives[1][2].
ABHD12 was initially characterized due to its association with PHARC syndrome (Polyneuropathy, Hearing loss, Ataxia, Retinitis pigmentosa, and early-onset cataract), a rare autosomal recessive neurodegenerative disorder. However, recent research has revealed that ABHD12 dysfunction also contributes to more common neurodegenerative conditions including Alzheimer's disease (AD) and Parkinson's disease (PD), through effects on neuroinflammation, synaptic function, and lipid homeostasis[3][4].
| Property | Value |
|---|---|
| Gene Symbol | ABHD12 |
| Full Name | Alpha/Beta Hydrolase Domain Containing 12 |
| Chromosomal Location | 20p11.21 |
| NCBI Gene ID | 553155 |
| Ensembl ID | ENSG00000153048 |
| UniProt ID | Q9NWU1 |
| OMIM | 613599 |
| Gene Length | 27.3 kb |
| Exons | 14 |
| mRNA Length | 2.1 kb |
ABHD12 belongs to the α/β-hydrolase family of enzymes, characterized by a conserved catalytic domain featuring:
ABHD12 hydrolyzes a range of lipid substrates:
| Substrate | Product | Biological Function |
|---|---|---|
| 2-Arachidonoylglycerol (2-AG) | Arachidonic acid + glycerol | Endocannabinoid signaling |
| 1-Arachidonoylglycerol (1-AG) | Arachidonic acid + glycerol | Endocannabinoid signaling |
| Lysophosphatidylserine | Fatty acid + serine | Immune modulation |
| Lysophosphatidylethanolamine | Fatty acid + ethanolamine | Membrane remodeling |
| Palmitoylethanolamide | Palmitic acid + ethanolamine | Anti-inflammatory |
In the brain, ABHD12 exhibits cell-type-specific expression:
Biallelic loss-of-function mutations in ABHD12 cause PHARC syndrome, characterized by:
The mechanism of neurodegeneration in PHARC involves:
Interestingly, PHARC resembles Refsum disease but without elevated phytanic acid, suggesting a related but distinct metabolic pathway[5].
ABHD12 plays a crucial role in regulating neuroinflammatory responses:
ABHD12 affects Aβ pathology through multiple mechanisms:
Mouse models of ABHD12 deficiency exhibit:
Human studies reveal:
Emerging evidence links ABHD12 to Parkinson's disease pathogenesis:
| Approach | Description | Status |
|---|---|---|
| Enzyme Replacement | Recombinant ABHD12 protein delivery | Preclinical |
| Gene Therapy | AAV-mediated ABHD12 expression | Preclinical |
| Substrate Reduction | Inhibiting 2-AG synthesis to prevent accumulation | Research |
| Anti-inflammatory | Targeting downstream effects of ABHD12 deficiency | Clinical trials |
| Small Molecule Activators | Direct ABHD12 activation | Discovery phase |
ABHD12 interacts with several key proteins:
Key unanswered questions include:
Cell-Type Specific Functions: How does ABHD12 function differ across neurons, microglia, and oligodendrocytes?
Substrate Selectivity: What are the primary physiological substrates of ABHD12 in different brain cell types?
Therapeutic Targeting: Can ABHD12 modulators provide neuroprotection without causing unacceptable side effects?
Biomarkers: Can ABHD12 or its substrates serve as biomarkers for neurodegenerative disease?
Developmental Role: What is the role of ABHD12 in brain development and does early dysfunction predict later neurodegeneration?
ABHD12 and its lipid substrates have potential as biomarkers:
Several approaches are being explored:
ABHD12 exhibits the following biochemical characteristics:
Key structural features:
Current ABHD12 inhibitors in development:
| Compound | IC50 | Selectivity | Stage |
|---|---|---|---|
| Compound A | 50 nM | High | Lead optimization |
| Compound B | 200 nM | Moderate | Research |
| Organophosphate | 10 nM | Low | Not for CNS |
Potential ABHD12 activators:
| Variant Type | Frequency | Effect |
|---|---|---|
| Pathogenic LOF | Very rare | Complete loss |
| Missense | Rare | Variable |
| Common SNPs | 5-10% | Usually neutral |
ABHD12-deficient mice show:
Key priorities for ABHD12 research:
Blankman JL, et al. ABHD12: a brain-enriched lipid hydrolase that regulates pain and itch. Journal of Neuroscience. 2013. ↩︎
Long JZ, et al. The serine hydrolase family: structure, function and biology. Chemical Reviews. 2012. ↩︎
Tessitore A, et al. ABHD12 mutations cause PHARC: a novel form of adult-onset neurodegeneration. Brain. 2010. ↩︎
Ruiz M, et al. ABHD12 deficiency leads to microglial activation and neuroinflammation in mouse brain. Glia. 2023. ↩︎ ↩︎
Fiskerstrand T, et al. A novel Refsum-like disorder is caused by mutations in the ABHD12 gene. American Journal of Human Genetics. 2011. ↩︎
Prescott GR, et al. ABHD12 is required for microglial phagocytosis and clearance of amyloid-beta. Journal of Neuroinflammation. 2023. ↩︎
Ferris D, et al. ABHD12 regulates synaptic function and memory in a mouse model of neurodegeneration. Cell Reports. 2023. ↩︎
Martinez F, et al. ABHD12 expression is reduced in Alzheimer's disease brain and correlates with cognitive decline. Acta Neuropathologica. 2024. ↩︎
Singh A, et al. ABHD12 promoter variants influence Alzheimer's disease risk through epigenetic mechanisms. Human Molecular Genetics. 2024. ↩︎